How dasatinib works

Dasatinib (Dasatinib) is a targeted therapy drug, mainly used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Its mechanism of action is mainly related to the inhibition of abnormal proteins BCR-ABL.

BCR-ABL is a fusion gene resulting from a chromosomal abnormality in Philadelphia and is typical of CML and some ALL patients. This fusion gene leads to the production of an abnormal protein that plays an abnormal role in regulating the growth and differentiation of white blood cells, causing the white blood cells to proliferate uncontrollably, thereby causing leukemia.

Dasatinib interferes the activity of BCR-ABL protein through its mechanism of action, thereby blocking the abnormal growth of white blood cells. Specifically, Dasatinib (Stardasatin) is a multi-target inhibitor that not only inhibits ABL kinase activity, but also inhibits multiple other related kinases, such as SRC family kinases. These kinases play important roles in cell signaling pathways, including processes such as cell proliferation, survival, and migration.

By inhibiting the activity of these kinases,dasatinib (Startase) blocks the abnormal proliferation of white blood cells and promotes apoptosis (cell death). In this way, dasatinib (Dasatinib) can effectively control the development of leukemia and improve the patient's condition.

It should be noted that although dasatinib (Stardas) has a significant inhibitory effect on BCR-ABL fusion gene, patients may experience some side effects during treatment, such as nausea, vomiting, fatigue, etc. Therefore, when using Dasatinib, doctors usually monitor the patient's condition and drug tolerance based on the patient's specific situation, and adjust the dose to achieve the best therapeutic effect.

In summary,dasatinib serves as a targeted therapy by interfering with BCR-ABLThe activity of the protein and other related kinases effectively controls the development of leukemia, providing patients with an important treatment option.